Riskpilot← Back to searchSign inGet full accessIMMUNOPHARMA AS
ASActiveOrg 994924273Mustads Vei 1A, 0283 OsloActivities of advertising agencies · NACE 7311Est. 201010 employeeswww.immunopharma.net
Revenue 2024
NOK 12,2B
+86401% vs 2023
EBITDA margin
-314.9%
-296725% vs 2023
Equity ratio
61.8%
Financial strength
Net profit 2024
NOK 13,7B
+12610% vs 2023
| Revenue | NOK 12,2B | +86401% |
| EBITDA | NOK -38,4B | -296725% |
| Net profit | NOK 13,7B | +12610% |
| Total assets | NOK 338,1B | +126515% |
| Equity | NOK 209B | +106927% |
| Employees | 10 | — |
Legal name
IMMUNOPHARMA AS
Org number
994924273
Legal form
Aksjeselskap
NACE code
7311 · Activities of advertising agencies
Founded
5. januar 2010
Share capital
NOK 13 865 442
Employees
10 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Utvikle, distribuere og selge ernæringsprodukter og farmasøytiske produkter samt tilknyttede tjenester med mer, samt investering i annen virksomhet.
Address
Mustads Vei 1A, 0283 Oslo
Phone
+4795216950
Email
info@immunopharma.net
Website
www.immunopharma.net
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 195 | 432 | 1 329 | 1 735 | 1 231 | 1 426 | 746 | 2 361 | 353 | 1 200 | 966 | 11 478 | 21 059 | 14 110 | 12 205 647 |
| Staff expenses | −297 | −323 | −738 | −346 | −336 | −490 | −523 | −559 | −696 | −982 | −0 | −10 000 | −15 478 | −13 428 | −15 924 096 |
| EBITDA | −2 037 | −3 131 | −2 454 | −501 | −547 | −569 | −3 658 | −7 974 | −10 580 | −10 566 | 3 962 | −15 587 | −6 486 | −12 950 | −38 438 075 |
| Depreciation & amort. | −8 | −60 | −63 | −54 | −3 | −0 | −0 | −0 | −0 | −0 | −567 | −552 | −196 | −18 | −79 194 |
| EBIT | −2 045 | −3 191 | −2 516 | −555 | −550 | −569 | −3 658 | −7 974 | −10 580 | −10 566 | 3 394 | −16 139 | −6 682 | −12 968 | −38 517 269 |
| Net financials | 0 | −6 | 34 | 4 | −2 | −24 | 1 | −27 | −26 | 824 | 10 554 | −24 949 | 42 029 | −87 367 | 57 211 333 |
| Profit before tax | −2 045 | −3 197 | −2 482 | −551 | −552 | −593 | −3 657 | −8 002 | −10 607 | −9 742 | 13 948 | −41 089 | 35 347 | −100 335 | 18 694 064 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −9 850 | 3 648 | −3 135 | −1 386 | 9 369 | 4 970 392 |
| Net profit | −2 045 | −3 197 | −2 482 | −551 | −552 | −593 | −3 657 | −8 002 | −10 607 | 108 | 10 300 | −37 954 | 36 733 | −109 704 | 13 723 672 |
| Item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1 145 | 1 882 | 2 737 | 1 387 | 1 330 | 1 832 | 3 723 | 25 140 | 20 784 | 289 515 | 307 897 | 358 690 | 367 491 | 267 015 | 338 081 366 |
| Equity | −1 695 | −459 | 1 073 | 522 | −30 | −623 | −2 215 | 15 434 | 7 822 | 132 992 | 162 845 | 256 166 | 305 327 | 195 301 | 209 024 714 |
| Long-term debt | 317 | 0 | 0 | 0 | 0 | 0 | 5 823 | 5 931 | 5 717 | 143 712 | 135 345 | 41 399 | 28 078 | 477 | 384 564 |
| Short-term debt | 2 523 | 2 025 | 1 664 | 865 | 1 361 | 2 455 | 115 | 3 775 | 7 246 | 12 811 | 9 707 | 61 125 | 34 085 | 71 237 | 128 672 088 |
| Total debt | 2 840 | 2 342 | 1 664 | 865 | 1 361 | 2 455 | 5 938 | 9 706 | 12 962 | 156 523 | 145 052 | 102 524 | 62 164 | 71 714 | 129 056 652 |
EBITDA margin
-314.9%
This company
15.8%
Market median
-2093% vs market
20102024
Equity ratio
61.8%
This company
38.2%
Market median
+62% vs market
20102024
Return on equity
6.6%
This company
18.4%
Market median
-64% vs market
20102024
Net profit margin
112.4%
This company
8.1%
Market median
+1288% vs market
20102024
Asset turnover
0.04×
This company
1.12×
Market median
-96% vs market
20102024
Debt / equity
0.62×
This company
0.62×
Market median
+0% vs market
20102024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PJ Deputy Member | Deputy Member | 2026 | — | — |
KC Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
RS Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
GH Deputy Member | Deputy Member | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
KØ | Board of Directors | 2021 | — | — |
| Board of Directors | 2021 | — | — | |
| Chairman | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Bohan & Co As | Company | 35.5% | 35.5% | 2024 |
Nicoline Invest As | Company | 23.6% | 23.6% | 2024 |
Six Sis Ag | Company | 6.4% | 6.4% | 2024 |
| Individual | 6.2% | 6.2% | 2022 | |
Equity Labs Sp. Z.O.O Ska | Company | 5.9% | 5.9% | 2024 |
Ubs Switzerland Ag | Company | 5.1% | 5.1% | 2024 |
| Individual | 4.4% | 4.4% | 2022 | |
Svenska Handelsbanken Ab | Company | 2.5% | 2.5% | 2024 |
Nordic Healthy Living As | Company | 1.9% | 1.9% | 2024 |
| Individual | 1.9% | 1.9% | 2022 | |
Universal Exports As | Company | 1.8% | 1.8% | 2022 |
Pro As | Company | 1.6% | 1.6% | 2024 |
| Individual | 1.6% | 1.6% | 2022 | |
Theo Investments As | Company | 1.6% | 1.6% | 2024 |
Noxa As | Company | 1.4% | 1.4% | 2024 |
Vestmark Research Consulting As | Company | 1.4% | 1.4% | 2024 |
3lp Norge As | Company | 1.2% | 1.2% | 2024 |
Rhumb Line As | Company | 1.2% | 1.2% | 2024 |
Fk Investment As | Company | 1.1% | 1.1% | 2023 |
Bgconsult As | Company | 1.1% | 1.1% | 2022 |
Avanza Bank Ab | Company | 1.0% | 1.0% | 2024 |
| Individual | 1.0% | 1.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
IMMUNOPHARMA AS 
Ip Eqology Holdco AsBoard members of IMMUNOPHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Piotr Jerzy Sierdzinski | Deputy Member | 0 companies |
| Knut Christian Espeseth | Chief Executive Officer | 0 companies |
| Ralf Schmidt | Chief Executive Officer | 0 companies |
| Geir Hetland | Deputy Member | 0 companies |
| Katarzyna Zdzislawa Maresz | Board of Directors | 0 companies |
| Kim Øien | Board of Directors | 0 companies |
| Frode Marc Bohan | Board of Directors | 0 companies |
| Kjetil Ramsøy | Chairman | 0 companies |